““molecularly targeted agents into the treatment of early-stage NSCLC. At this time, however, such an approach cannot be recommended outside a clinical trial. In the NCI-C JBR.19 trial, which was terminated early when gefitinib lost its U.S. Food and Drug Administration (FDA) approval, administration of the EGFR inhibitor gefitinib after resection of stage I to III NSCLC did not improve OS. Surprisingly, a subset analysis of patients with tumors harboring activating EGFR mutations, a population expected to derive particular benefit from such an approach, suggested the possibility of a detrimental effect from gefitinib. Similarly, the use of antiangiogenic agents and ALK inhibitors after surgery for advanced disease remains investigational.””
